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Abstract
A major problem in inflammatory bowel disease (IBD) is
the accumulation of highly activated T-helper cells that
are refractory to apoptosis induction. Hence, persistent
inflammatory lesions are prevalent and are the basis of
chronic disease. In IBD upregulation of costimulatory
molecules on lamina propria lymphocytes has been de-
scribed leading to apoptosis resistance. CD44 is a cell
adhesion molecule and a signalling receptor that func-
tions as a costimulatory molecule in T-cell activation.
Several variant isoforms of CD44 (CD44v) are expressed
by alternative splicing of variant exons encoding extra-
cellular regions. Particularly isoforms containing CD44v7
are expressed on T cells and macrophages in T-helper-1
(Th1)-mediated chronic inflammation and autoimmune
diseases. In this review recent data on the functional
involvement of CD44v7 isoforms in IBD are discussed. In
a mouse model of experimental colitis blockade or dele-
tion of CD44v7 protects mice from severe intestinal
inflammation by inducing apoptosis in lamina propria
mononuclear cells. Recently, we observed that in lamina
propria mononuclear cells from the inflamed but not
uninflamed mucosa of patients with Crohn’s disease,
blockade of CD44v7 isoforms also induces apoptosis.
The finding that obstruction of CD44v7 isoforms can
antagonize Th1-cytokine-dependent immune pathology
identifies CD44v7 as a target in the treatment of inflam-
matory diseases such as IBD, rheumatoid arthritis, multi-
ple sclerosis and other autoimmune diseases in which
CD44v7 isoforms are upregulated.
Copyright © 2003 S. Karger AG, Basel
Introduction
The mucosal immune system is comprised of anatomi-
cally defined lymphoid microcompartments, such as
Peyer’s patches in the small intestine, appendix, and soli-
tary follicles in the large intestine and rectum, nasal
mucosa and tonsils, which serve as principal mucosal
inductive sites where immune responses are initiated. It
also contains diffuse accumulations of large numbers of
lymphoid cells that are either distributed in the lamina
propria or interspersed among epithelial cells in mucosal
tissues and glands, and form the effector sites where
immune responses are expressed [1, 2]. Three major
adaptive effector mechanisms participate in the immune
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defense of mucosal surfaces. Secretory IgA antibody for-
mation and antigen-specific cell-mediated cytotoxicity
are the primary mechanisms involved in antimicrobial
defense in the mucosal epithelium. The induction of IgA
production to protein antigens is highly dependent on T-
helper cells [3, 4]. In addition, mainly through the produc-
tion of regulatory cytokines, regulatory T cells contribute
as a third form of mucosal defense. The tissue microenvi-
ronment, the cytokine milieu and the antigen itself in-
fluence the further differentiation of CD4+ nai¨ve T cells
to T-helper (Th)-0 cells that produce both interferon
(IFN)-Á and interleukin (IL)-4 and further to a Th1- or
Th2-directed immune response. Mucosal uptake of anti-
gens may result in the development of immunity or toler-
ance, or even both, the decision being taken in the epithe-
lium or underlying lymphoid tissue and it is mainly deter-
mined by the nature and presentation of the antigen.
Besides the strength of the T-cell receptor signal or anti-
gen density, the second signal in T-cell activation is pro-
vided by engagement of one or more T-cell surface recep-
tors with their ligands on antigen-presenting cells. At
present, the role of these pairs of costimulatory molecules,
like CD28-B7 and CD154-CD40, in regulating Th1 ver-
sus Th2 immune responses in vivo is not known in detail
[5].
CD44 as a Cell Adhesion Molecule and a
Signalling Receptor
One of the lymphocyte markers which is supposed to
work as a costimulatory molecule is the transmembrane
glycoprotein CD44. The role of CD44 as a hyaluronan
receptor has been known for many years and defines
CD44 as a cell adhesion molecule [6]. However, there is
also substantial evidence that CD44 is a potent signalling
receptor. Early studies using anti-CD44 monoclonal anti-
bodies to trigger the receptor established that CD44 is a
costimulatory molecule on T cells [7–10]. For example,
stimulation through CD44 has been reported to enhance
T-cell proliferation and IL-2 production independent of
CD28 [7, 8, 10, 11]. Furthermore, it has been shown that
ligation of the costimulatory molecule CD40 rapidly
upregulates CD44 expression on T cells [11]. In addition
to T cells, stimulation through CD44 enhances macro-
phage production of proinflammatory mediators, includ-
ing IL-12, IL-1ß, and tumor necrosis factor-· (TNF-·)
[12, 13]. In the last decade, it has been reported that anti-
CD44 antibodies have potent anti-inflammatory activity
in vivo [14–16], most probably resulting from an anti-
body-mediated (anti-panCD44 antibody IM7) shedding
of CD44 from leukocytes, thus preventing cell recruit-
ment and activation [17]. Although IM7 has been taken
under consideration for clinical immunotherapy in au-
toimmune disease and cancer, recent data pointed out its
harmful side effects, such as systemic shock [18].
Whereas the standard form of CD44 shows a broad
expression on various cells of epithelial and hematopoiet-
ic origin, alternative splicing of at least ten exons, encod-
ing variant extracellular regions, generates a large number
of isoforms [19]. Expression of these so-called variant iso-
forms is strictly controlled [20] and confined to specific
states of lymphocyte activation, hematopoiesis and tumor
progression [21–24].
Specific Expression of CD44 Variant Isoforms
v6 and v7 on Activated Lymphocytes
In the mouse model for experimental colitis, it has
been shown that isoforms containing CD44v6 and v7 are
hardly expressed on resting lymphocytes in the spleen,
lymph nodes, peripheral blood or Peyer’s patches [21].
After in vitro stimulation via a T-cell mitogen or a nomi-
nal antigen, however, there was upregulation of CD44v6
and v7. Expression patterns of these splice variants de-
fined the molecules as activation markers in gut-associat-
ed lymphoid tissue. Particularly at inflammatory sites on
lamina propria lymphocytes CD44v6 and v7 isoforms are
strongly upregulated. In addition, since CD44v6 and v7
expression during activation was transient, it was tempt-
ing to speculate that these two variant isoforms are func-
tionally active in lymphocyte activation [25].
Blockade of CD44 Variant Isoforms Cures
Experimental Colitis in the Mouse
In experimental colitis CD44v7 expression is upregu-
lated on mononuclear cells of intestinal inflammatory
lesions in Th1-polarized inflammation. Unlike in vitro
stimulation, expression of CD44v7 was not transient, but
persistent [26]. Based on these data, it was demonstrated
that administration of a monoclonal antibody against
CD44v7 [27], but not anti-CD44v6, cures most mice with
2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced coli-
tis. The colitis induced by the haptenizing agent TNBS
has been described as Th1-cytokine-driven inflammation
[28]. In this model after an initial increase in the Th1 cyto-
kine IFN-Á, the therapeutic effect of anti-CD44v7 anti-
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body treatment was accompanied by an increased produc-
tion of IL-10 and a decreased production of IL-12 in lami-
na propria lymphocytes as well as systemically [29]. Fur-
thermore, co-administration of a neutralizing antibody to
IL-10 (2A5.7) completely abrogated the therapeutic effect
of anti-CD44v7 antibody in TNBS colitis, which indi-
cates the central role of IL-10 in CD44v7 regulation. It
has been suggested that the CD44v7-specific antibody
functions by regulating an overshooting Th1 reaction in
chronic inflammation [30].
CD44v7 Is Essential for a Th1-Type Immune
Response
To further define the role of CD44v6 and v7 in colitis,
mice bearing a targeted deletion of exons v6 and v7 of
CD44 were generated without affecting the expression of
the other exons. Under normal conditions, these mice
have no altered phenotype or changes in the distribution
of cell subpopulations in the lymphatic systems. Mice
with TNBS-induced colitis are protected from severe
inflammation and wasting disease by deletion of CD44v7
alone and v6/v7. Adoptive transfer of bone marrow cells
clearly shows that expression of CD44v7 on hematopoiet-
ic cells but not on intestinal epithelia is necessary to estab-
lish intestinal inflammation [26]. Moreover, crossing
CD44v6/v7 mutants with IL-10-deleted mice, which de-
velop chronic enterocolitis [31], is protective against ex-
perimental colitis for an observation period of more than
1 year [26].
Why and at which stage is the region encoded by
CD44v6 and v7 important in intestinal inflammation?
According to the expression profile and proliferation
studies, CD44v7 functions as a costimulatory molecule
and might be a receptor molecule on antigen-presenting
cells for an as yet unidentified ligand. We have shown
recently that CD44v7 is upregulated by CD40 ligation
[32], which promotes clonal T-cell expansion, and delays
activation-induced cell death [33–35]. The ability of
CD40 ligation to modulate an immune response towards
cell proliferation and apoptosis may depend on the avail-
ability of additional coreceptors or ligands that are tran-
siently upregulated during T-cell activation, e.g. CD44v7.
Most interestingly, analysis of cell death in the inflamed
lesions revealed that mononuclear cells in the CD44v7-
and CD44v6/v7-deleted infiltrates had higher rates of
apoptosis as compared to those from wild-type mice. The
increase in apoptotic markers, measured as active caspase
3, p85 PARP, and TUNEL activity is restricted to in-
flamed lesions in CD44v7 (and v6/v7) null mice, indicat-
ing that blockade of CD44v7 may be a highly specific
therapeutic approach in inflammatory bowel disease [26].
Recent data in murine models of experimental autoim-
mune encephalomyelitis and rheumatoid arthritis un-
equivocally demonstrate that not the standard region of
CD44, whose expression is unaffected by the mutation,
but rather the region encoded by exon v7, is causally
involved in autoimmune or chronic inflammation [for
review see 36].
Blockade of CD44v7 Induces Apoptosis in
Patients with Crohn’s Disease
In the pathogenesis of inflammatory bowel disease,
such as Crohn’s disease or ulcerative colitis, dysregulated
CD4+ T-cell activation and proliferation in the intestinal
mucosa is a key component [37]. Crohn’s disease is char-
acterized by a Th1-directed immune response with in-
creased CD4+ T-cell production of IFN-Á and activated
macrophages that secret TNF-· and IL-12 [38]. Data
obtained in animal models of experimental colitis and
humans suggest that Crohn’s disease can result from a
defect in counter regulating the immune response, e.g. by
TGF-ß, to normal mucosal antigens, which initiates and/
or sustains chronic inflammation [39]. Although both
CD44v6 and CD44v7 are upregulated upon mitogenic
stimuli in vitro, we have found an increased expression of
CD44v7 but not CD44v6 in the peripheral blood and
inflamed mucosa of patients with Crohn’s disease, but not
ulcerative colitis [32, 40]. Since deletion of CD44v7 pro-
tects mice from colitis by induction of apoptosis of acti-
vated T cells and macrophages, blockade of CD44v7
might be a new approach to re-induce programmed cell
death of activated cells in chronic inflammatory condi-
tions in humans. Indeed, we demonstrate that in patients
with Crohn’s disease blockade of CD44v7 with a mono-
clonal antibody induces apoptosis in the lamina propria
mononuclear cells of inflamed mucosa, but not in the
non-inflamed mucosa of Crohn’s disease or control tissue.
This effect is not detected in the lamina propria of
patients with active ulcerative colitis or acute diverticuli-
tis. In addition, apoptosis induction is also obtained using
a recombinant CD44 variant fusion protein containing
CD44v7.
Finally, the apparent influence of CD44v7 on IL-10
production needs to be discussed further. We have de-
scribed in the mouse model that IL-10 becomes signifi-
cantly upregulated by curative treatment with anti-
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Fig. 1. A In the normal gut mucosa Peyer’s
patch lymphocytes express small levels of
CD44v7. Antigen exposure induces oral tol-
erance, mediated by regulatory cytokines
such as TGF-ß and apoptosis of effector
cells. B In chronic inflammatory bowel dis-
ease costimulatory molecules such as CD40
and CD44 that give contra-apoptotic signals,
are upregulated on lamina propria mononu-
clear cells sustaining the chronic inflamma-
tion in the gut. LPL = Lamina propria lym-
phocytes.
CD44v7 [29]. In a clinical study an increased number of
IL-10-producing peripheral blood mononuclear cells in
patients with inflammatory bowel disease has been de-
scribed after in vitro culture with anti-CD44v7 [32].
Interestingly, anti-CD44v7-stimulated T cells as well as B
cells and monocytes produce IL-10 [32]. In line with these
findings, it has been described that Fas-mediated apopto-
sis of lymphoid cells leads to rapid production of anti-
inflammatory cytokines such as IL-10. In these studies,
the apoptotic cells containing IL-10 were responsible for
the activation of immune deviation through interaction
with antigen-presenting cells [41, 42]. Thus, apoptotic cell
death of immune effector cells and tolerance are linked
through the production of an anti-inflammatory cytokine
in order to minimize dysregulated immune reactions, e.g.
a Th1-cytokine response that might compromise organ
integrity [43, 44]. Since apoptosis induction might restore
immunological tolerance in intestinal mucosa, neutraliz-
ing CD44v7 might provide a promising therapeutic ap-
proach in inflammatory bowel disease (fig. 1).
Conclusion
The ubiquitously expressed CD44 standard molecule
is the major cellular receptor for hyaluronic acid and a
signalling receptor in T-cell activation. The present data
on CD44 variant isoforms, which are expressed in a high-
ly restricted manner, suggest a specific involvement of the
variant isoform CD44v7 in the gut immune system.
CD44v7 is essential for Th1-cytokine-mediated experi-
mental colitis in distinct mouse models and upregulated
in the inflamed mucosa in Crohn’s disease. In the in-
flamed mucosa neutralization of the costimulatory mole-
cule CD44v7 by a monoclonal antibody or a recombinant
fusion protein induces apoptosis in human as well as
mouse lamina propria mononuclear cells. Thus, CD44v7
appears to endow lamina propria mononuclear cells with
resistance towards apoptosis leading to sustenance of the
chronic inflammation in the gut. Many questions remain
regarding the varied functions of the CD44 antigen, its
multiple isoforms, and its multiple ligands. While hyalu-
ronan polymers are components of the extracellular ma-
trix and a substrate for CD44-mediated cell adhesion,
hyaluronan fragments are signalling molecules which acti-
vate the immune system at the site of inflammation [45].
These hyaluronan fragments are themselves capable of
activating NF-ÎB [46] and are present at abnormally high
levels in chronic inflammatory conditions such as rheu-
matoid arthritis [47, 48]. Therefore, binding of matrix
components via CD44 variant isoforms might mediate
the specific activation signal in chronic inflammation
[49]. Furthermore, proteolytic release of the CD44 intra-
cellular domain may lead to direct influence of transcrip-
tional activation of tumor-associated genes [50]. The role
of CD44 in apoptosis is controversially discussed. Recent
data indicate that deletion of the hyaluronan binding
region induces prolonged inflammation in the lung by
accumulation of hyaluronan fragments and decreased
clearance of apoptotic neutrophils [51]. Others, however,
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have shown that binding of CD44 to hyaluronan gener-
ates an anti-apoptotic effect [52]. Also we have shown that
CD44v7 isoforms protect gut mononuclear cells from
undergoing programmed cell death in chronic inflamma-
tion [26]. Differential regulation of cell activation and cell
death via CD44 and its variant isoforms maybe the result
of different ligand interactions, which may cause confor-
mational changes. These changes will have an impact on
the interaction with other surface molecules, which still
need to be identified. Future therapeutic strategies may
thereby include the exploitation of CD44 variant iso-
forms and the signalling by matrix components to directly
induce apoptosis.
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